D. Akcora-Yildiz Et Al. , "HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma," Chemical Biology and Drug Design , vol.102, no.2, pp.262-270, 2023
Akcora-Yildiz, D. Et Al. 2023. HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma. Chemical Biology and Drug Design , vol.102, no.2 , 262-270.
Akcora-Yildiz, D., GÖNÜLKIRMAZ, N., ÖZKAN, T., BEKSAÇ, M., & SUNGUROĞLU, A., (2023). HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma. Chemical Biology and Drug Design , vol.102, no.2, 262-270.
Akcora-Yildiz, Dilara Et Al. "HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma," Chemical Biology and Drug Design , vol.102, no.2, 262-270, 2023
Akcora-Yildiz, Dilara Et Al. "HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma." Chemical Biology and Drug Design , vol.102, no.2, pp.262-270, 2023
Akcora-Yildiz, D. Et Al. (2023) . "HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma." Chemical Biology and Drug Design , vol.102, no.2, pp.262-270.
@article{article, author={Dilara Akcora-Yildiz Et Al. }, title={HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma}, journal={Chemical Biology and Drug Design}, year=2023, pages={262-270} }